Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of sac-TMT with or without pembrolizumab versus physician's choice chemotherapy in first-line PD-L1-low metastatic or unresectable locally recurrent triple-negative breast cancer
MOH_2025-03-02_013836Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan and pembrolizumab in breast cancer and triple-negative breast cancer (TNBC) (3 arms), sponsored by Merck & Co. Primary endpoints: Progression-free survival and Overall survival. Started Jan 2025; status: recruiting.
02
Drugs
sacituzumab tirumotecanpembrolizumab
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on MOH_2025-03-02_013836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-03-02_013836.